A CRO cut monitoring costs by over 50% on a global Phase IV oncology study using CluePoints' risk-based approach.
A traditional monitoring strategy for the global oncology study was projected to cost $40 million. The CRO restructured oversight around risk-based quality management with CluePoints. The page states monitoring costs were reduced by 50%+.
CluePoints is a risk-based quality management and central statistical monitoring platform used by sponsors and CROs to detect data quality, fraud and safety issues in trials
This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.
Published by CluePoints on its own site — read the original case study on lp.cluepoints.com ↗
Note: Page does not say which CluePoints products were used.
Related use cases
- 01CluePoints' data quality assessment exposed a systemic issue behind one positive outlier in a Phase I neurology study.
- 02CluePoints' central monitoring caught missing gluten tests and misclassified adverse events in a trial of fewer than 50 subjects.
- 03A top-50 sponsor found data manipulation at a Phase II site; CluePoints' platform flagged it retrospectively and could catch it earlier.
- 04A dermatology company monitored 24+ sites and 680 participants in a Phase 3 study with CluePoints' ML-based RBQM.
- 05Transforming Content Operations for 2x Faster Time to Market
- 06Astellas: Breaking Access Barriers with Veeva Compliant Chat